Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2017Molecular Therapy — Methods & Clinical DevelopmentOpen Access

Emerging Issues in AAV-Mediated In Vivo Gene Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

PCPasqualina ColellaGRGiuseppe RonzittiFMFederico Mingozzi

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Colella et al. (2017) studied this question.

synapsesocial.com/papers/69d8331b05ee2ba81dbef2cchttps://doi.org/10.1016/j.omtm.2017.11.007
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dystrophin Immunity in Duchenne's Muscular Dystrophy2010 · 674 citations
  2. 2Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model2017 · 75 citations
  3. 3MyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV2012 · 55 citations
  4. 4Proteasome Inhibitors Decrease AAV2 Capsid derived Peptide Epitope Presentation on MHC Class I Following Transduction2009 · 108 citations
  5. 5Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy2010 · 156 citations